Saltar al contenido
Merck

14701C

SAFC

EX-CELL® Glycosylation Adjust (Gal +)

protein quality supplement

Fabricación farmacéutica

Sinónimos:

N-linked glycosylation reagent

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

Quality Level

form

liquid

quality

GMP
chemically defined

technique(s)

cell culture | mammalian: suitable

impurities

Sterility Tested, pH, Endotoxin, and Appearance

suitability

suitable for manufacturing use

storage temp.

2-8°C

General description

A protein quality supplement that targets glycosylation attributes, EX-CELL® Glycosylation Adjust (Gal+) allows users to easily and quickly achieve desired N-linked glycosylation by increasing the galactose site occupancy on the oligosaccharide to a higher level. Supplementation demonstrates 2- to 4-fold increases in G1F and G2F distributions when compared to processes without addition of the product. The product can be used with a broad range of cell lines, is scalable, and is regulatory friendly.
GMP concentrated solution. Intended as a cell culture supplement. Recommended titration starting point, % volume/volume.

Packaging

14701C-100ML
14701C-1000ML

Linkage

Submit the EX-CELL Glycosylation Adjust (Gal +) request form to get in touch with a SAFC representative.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Artículos

Our protein quality supplement, EX-CELL® Glycosylation Adjust (Gal+), provides customers with a novel chemically defined product which targets glycosylation attributes.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico